Ivosidenib
ATC L01XM02 · 9 markets · 12 records
AU 3 records · 2 strengths
- 250 mgtabletTIBSOVOTIBSOVO ivosidenib 250 mg film-coated tablet bottle
Records without a stated strength · 1 TIBSOVO
US 1 records · 1 strengths
- 250 mgtabletTIBSOVO
GB 1 records · 1 strengths
- 250 mgtabletTIBSOVO
CA 1 records · 1 strengths
- 250 mgtabletTIBSOVO
SG 1 records · 1 strengths
- 250 mgtabletTIBSOVO
ES 1 records · 1 strengths
- 250 mgtabletTIBSOVO
TW 1 records · 1 strengths
- 250 mgtabletTIBSOVO拓舒沃膜衣錠 250毫克
HK 1 records · 1 strengths
Records without a stated strength · 1 TIBSOVO
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 TIBSOVO
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|---|
| 250 mg tablet | TIBSOVO | TIBSOVO | TIBSOVO | TIBSOVO TIBSOVO ivosidenib 250 mg film-coated tablet bottle | TIBSOVO | TIBSOVO | TIBSOVO 拓舒沃膜衣錠 250毫克 | ||
unknown | TIBSOVO | TIBSOVO | TIBSOVO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.